| Clinical data | |
|---|---|
| Other names | SP624 |
| Routes of administration | Oral |
| Drug class | Sirtuin-6 (SIRT6) activator |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C19H17ClN2O6 |
| Molar mass | 404.80 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Forvisirvat (INN, USAN; developmental code name SP-624) is a selective sirtuin-6 (SIRT6) activator which is under development for the treatment of major depressive disorder and schizophrenia. It is taken by mouth. The drug produces antidepressant-like effects in multiple animal models of depression. As of January 2025, forvisirvat is in phase 2/3 clinical trials for major depressive disorder and is in phase 1/2 clinical trials for schizophrenia. It is under development by Sirtsei Pharmaceuticals and Arrivo BioVentures.